Invivyd’s (IVVD) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $9.00 target price on the stock.

IVVD has been the topic of a number of other research reports. Morgan Stanley dropped their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research note on Monday, February 24th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Trading Up 1.0 %

Shares of IVVD stock opened at $1.06 on Wednesday. The stock has a market cap of $126.79 million, a PE ratio of -0.54 and a beta of 0.61. The company’s fifty day moving average price is $0.90 and its 200-day moving average price is $0.87. Invivyd has a 12 month low of $0.35 and a 12 month high of $4.74.

Insiders Place Their Bets

In other Invivyd news, Director Terrance Mcguire sold 119,805 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the completion of the transaction, the director now owns 3,568,274 shares of the company’s stock, valued at approximately $1,498,675.08. The trade was a 3.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Invivyd

A number of hedge funds have recently bought and sold shares of IVVD. Proficio Capital Partners LLC purchased a new position in Invivyd in the 3rd quarter worth about $27,000. State Street Corp increased its position in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares during the last quarter. Barclays PLC increased its position in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after purchasing an additional 75,780 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after purchasing an additional 222,375 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Invivyd during the 4th quarter valued at about $74,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.